🏛️ Verified NIH Record • Updated 2025-10-24
Role of ROS and cAMP-PKA Biomarkers in ADPKD (NCT07217158)
🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Mayo Clinic
🩺 Plain-English Summary (8th-Grade Level)
The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (7 items).
Location: Mayo Clinic — Rochester, Minnesota
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Class 2, according to imaging classification
- A concomitant systemic disease affecting the kidney
- Diabetes mellitus
- Predicted urine protein excretion in \>1 g/24 hrs. and or abnormal urinalysis
- Use of antioxidants, i.e., vitamins, Nrf2 activators
- Patients who are part of an interventional study or taking tolvaptan
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Mayo Clinic — Rochester, Minnesota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.